Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AVI BioPharma has completed the purchase of a GMP manufacturing building in Corvallis, Ore for $3.3 million.
Subscribe to our email newsletter
The 34,000-square-foot facility will house additional capability for the large-scale GMP production of AVI’s proprietary phosphorodiamidate morpholino oligomers (PMOs). Additional capacity for both of these processes will be necessary to meet its anticipated bulk drug supply requirements. The company will continue to occupy the building it currently leases in Corvallis, which has research space and a smaller-scale GMP manufacturing site.
“When our GMP build-out is completed, we believe that this new facility will provide the space and production capacity we anticipate needing to advance our Neugene antisense programs,” said Dwight Weller, senior vice president of chemistry and manufacturing at AVI BioPharma.
“We anticipate needing to produce larger amounts of material for advancing clinical trials and for eventual commercial production.”
AVI’s lead Neugene antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition, AVI’s antiviral program uses Neugene antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, ebola virus and influenza A virus.